mining the market

Investors + news

We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.

see our business strategy in action

Eagle Pharmaceuticals 2021 Annual Report

Investors Menu


Featured Press Release

Abstracts to be presented cover preclinical data on RYANODEX® (dantrolene sodium) for injectable suspension in Acute Radiation Syndrome and Traumatic Brain Injury WOODCLIFF LAKE, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today
See More
Total revenue for Q1 2023 was $66.3 million, compared to $115.9 million in Q1 2022 Q1 2023 net income was $0.44 per basic and diluted share and adjusted non-GAAP net income 1 was $1.27 per basic and $1.26 per diluted share Q1 2023 adjusted non-GAAP EBITDA of $22.3 million Q1 2023 net sales of
See More
-- Byfavo 1 is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less WOODCLIFF LAKE, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Centers
See More

Upcoming Events & Presentations

No items found.

Change % Volume Data as of 03/31/2023 11:39 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

Communications, Inc.
Lisa M. Wilson,

For all other media inquiries, please contact us.